UCB stock stays in focus as BIMZELX data reaches ACR Convergence
Published on 11/10/2026 at 18:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSClinical momentum meets investor focus
- BIMZELX delivered stronger Week 24 ACR50 responses than risankizumab in the BE BOLD psoriatic arthritis study.
- The Week 24 comparison was exploratory, while the Week 16 primary endpoint showed statistically significant superiority.
- UCB's broader ACR Convergence program covers 18 abstracts across immunology indications.
UCB stock remains in focus on Tuesday, November 10, as the company presents full Week 24 findings from the BE BOLD study at ACR Convergence in Orlando. In its investor materials, UCB describes BIMZELX as a key growth driver in its immunology portfolio.
BIMZELX achieved an ACR50 response in 54.9% of patients at Week 24, compared with 43.8% for risankizumab, according to the company's BE BOLD results. The study enrolled 553 adults with active psoriatic arthritis and compared the treatments in a randomized, double-blind Phase 3b design.
Clinical lead carries important caveats
The Week 24 ACR50 comparison was exploratory. At Week 16, the primary endpoint, ACR50 responses reached 49.1% with BIMZELX and 38.0% with risankizumab, a difference UCB described as statistically significant.
Secondary measures remained numerically higher for BIMZELX but did not reach statistical significance after sequential testing stopped at the first ranked secondary endpoint. Localized Candida infections occurred in 2.9% of BIMZELX-treated patients versus 0.7% for risankizumab; UCB said the cases were mild or moderate and did not lead to treatment discontinuation.
Stock comparison since the latest report
UCB stock traded at 295.05 euros on Lang & Schwarz at 18:14 CET on Tuesday, November 10. That was 1.22% below the 298.70-euro quote at 11:20 CET cited in the latest report published earlier the same day. This is a separate comparison from any Xetra-session performance.
UCB company and stock facts
- Company: UCB S.A.
- ISIN: BE0003739530
- Primary listing: Euronext Brussels
- Lang & Schwarz quote: 295.05 euros at 18:14 CET on November 10, 2026
- Clinical focus: BIMZELX in psoriatic arthritis
European healthcare shares remain sensitive to clinical readouts, regulatory milestones and product launches. See the latest Euro Stoxx 50 market coverage.
